Information Provided By:
Fly News Breaks for December 30, 2019
AXSM
Dec 30, 2019 | 14:55 EDT
Ladenburg analyst Matthew Kaplan raised his price target on shares of Axsome Therapeutics to $165 from $139 as he believes the "impressive" top-line AXS-07 MOMENTUM Phase 3 migraine study results increase the likelihood for approval of the drug. The analyst, who notes that Axsome plans to file a new drug application for AXS-07 in the second half of 2020, reiterated his Buy rating on the stock.
News For AXSM From the Last 2 Days
There are no results for your query AXSM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.